top of page
TELESCOPE
NEOADJUVANT PEMBROLIZUMAB AND CARBOPLATIN PLUS PACLITAXEL FOR STAGE I TRIPLE-NEGATIVE BREAST CANCER (TELESCOPE)
CLINICAL TRIAL DETAILS
THE STUDY WILL EVALUATE AN ANTHRACYCLINE-FREE REGIMEN FOR PATIENTS WITH T1CN0 TRIPLE-NEGATIVE BREAST CANCER. THE PRIMARY OBJECTIVE IS TO EVALUATE THE PATHOLOGICAL COMPLETE RESPONSE RATE DEFINED AS THE PERCENTAGE OF PATIENTS WITH YPT0/IS, YPN0 AT SURGERY BASED ON LOCAL ASSESSMENT.
COUNTRY
STATUS
TUMOR TYPE
PHASE
N
SITES
Breast Cancer
30
II
Spain
Set-up
PRESS RELEASE
-
SCIENTIFIC IMPACT
BLOG ARTICLES RELATED
-
TRIAL SITES
-
bottom of page